QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) 期刊论文 LEUKEMIA & LYMPHOMA, 2019, 卷号: 60, 期号: 1 作者:  Robak, Tadeusz;  Huang, Huiqiang;  Jin, Jie;  Zhu, Jun;  Liu, Ting 收藏  |  浏览/下载：24/0  |  提交时间：2019/12/05 Mantle cell lymphoma  R-CHOP  VR-CAP  bortezomib  LYM-3002  dose intensity   Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM-3002 study 期刊论文 Blood, 2014, 卷号: 124 作者:  Robak T., Huang H., Jin J., Zhu J., Liu T., Samoilova O.S., Pylypenko H., Verhoef G., Siritanaratkul N., Osmanov E.A., Alexeeva J., Pereira J., Mayer J., Hong X., Maeda Y., Pei L., Rooney B., Van De V 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study 会议论文 作者:  Robak, Tadeusz;  Huang, Huiqiang;  Jin, Jie;  Zhu, Jun;  Liu, Ting 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/19